DBV Technologies (DBV)

Currency in EUR
1.71
+0.01(+0.59%)
Closed·
DBV Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
DBV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.691.76
52 wk Range
0.512.38
Key Statistics
Prev. Close
1.71
Open
1.7
Day's Range
1.69-1.76
52 wk Range
0.51-2.38
Volume
340.16K
Average Volume (3m)
789.32K
1-Year Change
101.41%
Book Value / Share
0.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DBV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.52
Downside
-11.11%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

DBV Technologies News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell

DBV Technologies Company Profile

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Employees
109
Market
France

Compare DBV to Peers and Sector

Metrics to compare
DBV
Peers
Sector
Relationship
P/E Ratio
−2.2x−0.6x−0.5x
PEG Ratio
0.100.000.00
Price/Book
3.2x2.5x2.6x
Price / LTM Sales
71.7x6.5x3.3x
Upside (Analyst Target)
−10.6%67.2%43.5%
Fair Value Upside
Unlock15.9%6.9%Unlock

Analyst Ratings

2 Buy
0 Hold
1 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1.52
(-11.11% Downside)

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
-0.27 / -0.0313
Revenue / Forecast
1.31M / 640.32K
EPS Revisions
Last 90 days

DBV Income Statement

People Also Watch

122.00
EXA
-4.54%
5.90
NANOB
-1.50%
2.5300
ALCPB
-2.32%
68.00
TEPRF
-0.58%
249.30
ESLX
-1.42%

FAQ

What Stock Exchange Does DBV Technologies Trade On?

DBV Technologies is listed and trades on the Paris Stock Exchange stock exchange.

What Is the Stock Symbol for DBV Technologies?

The stock symbol for DBV Technologies is "DBV."

What Is the DBV Technologies Market Cap?

As of today, DBV Technologies market cap is 233.32M.

What Is DBV Technologies's Earnings Per Share (TTM)?

The DBV Technologies EPS (TTM) is -1.13.

When Is the Next DBV Technologies Earnings Date?

DBV Technologies will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is DBV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has DBV Technologies Stock Split?

DBV Technologies has split 0 times.

How Many Employees Does DBV Technologies Have?

DBV Technologies has 109 employees.

What is the current trading status of DBV Technologies (DBV)?

As of 07 Aug 2025, DBV Technologies (DBV) is trading at a price of 1.71, with a previous close of 1.71. The stock has fluctuated within a day range of 1.69 to 1.76, while its 52-week range spans from 0.51 to 2.38.

What Is DBV Technologies (DBV) Price Target According to Analysts?

The average 12-month price target for DBV Technologies is EUR1.52, with a high estimate of EUR1.74 and a low estimate of EUR1.3. 2 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -11.11% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.